Single-dose therapy for giardiasis in school-age children

Krisana Pengsaa1, Kriengsak Limkittikul, Chanathep Pojjaroen-anant

  • 1Department of Tropical Pediatrics, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand. tmksp@mahidol.ac.th

Insights

A combination of albendazole and praziquantel showed a high cure rate for giardiasis in children, comparable to tinidazole. This combined therapy may also treat co-existing helminth infections.

Area of Science:

  • * Infectious Diseases
  • * Pediatric Parasitology
  • * Clinical Pharmacology

Background:

  • * Giardiasis is a common intestinal infection in school-age children.
  • * Effective and safe treatment options are crucial for managing giardiasis and preventing its spread.
  • * Investigating novel therapeutic combinations can improve treatment outcomes.

Purpose of the Study:

  • * To evaluate the efficacy of a combined albendazole and praziquantel regimen for treating giardiasis in children.
  • * To compare this combination therapy with single-agent albendazole and tinidazole treatments.

Main Methods:

  • * A randomized controlled trial involving 84 school-age children with giardiasis.
  • * Three treatment groups: albendazole-praziquantel combination, albendazole alone, and tinidazole alone.
  • * Cure was defined as the absence of Giardia in two consecutive stool samples.

Main Results:

  • * The albendazole-praziquantel combination achieved a parasitological cure rate of 74.2%.
  • * Tinidazole showed the highest cure rate (92.6%), followed by the combination therapy.
  • * Albendazole monotherapy had a cure rate of 50%. No significant difference was found between the combination and tinidazole groups.

Conclusions:

  • * The combined albendazole-praziquantel regimen is a safe and potentially effective alternative for treating giardiasis in children.
  • * This combination offers the advantage of treating concurrent helminth infections.
  • * Further studies are needed to optimize the dosage of the combination therapy for Giardia intestinalis.

Related Concept Videos

Giardiasis01:12

Giardiasis

Giardiasis is a globally prevalent intestinal infection caused by the protozoan parasite Giardia duodenalis (also known as G. lamblia or G. intestinalis). This flagellated protozoan is the most frequently identified intestinal parasite in the United States and worldwide. Transmission primarily occurs via the fecal-oral route, with infection arising from ingestion of water or food contaminated with cysts. Individuals in low-resource settings, international travelers, outdoor enthusiasts, daycare...
Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents01:18

Drugs Affecting GI Tract Motility: Antimicrobials as Antidiarrheal Agents

Acute diarrhea, a common gastrointestinal disturbance, is characterized by the rapid evacuation of fluid stools, leading to an excessive weight in fluid. This condition typically arises from disorders affecting intestinal water and electrolyte transport. It can be triggered by an increased osmotic load within the intestine, excessive secretion of electrolytes and water, mucosal exudation of protein and fluid, or altered intestinal motility. The primary risks of acute diarrhea are dehydration...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Dosage Regimen: Multiple Oral Dosage01:25

Dosage Regimen: Multiple Oral Dosage

Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...